Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rates and a slightly higher interest charge than previously anticipated. Notes Hikma has launched oncology injectable products in the Middle East and North Africa, and says this is
Read moreBroker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0633 GMT [Dow Jones] Morgan Stanley downgrades Hikma Pharmaceuticals (HIK.LN) to equalweight from overweight but raises price
Read more0633 GMT [Dow Jones] Morgan Stanley downgrades Hikma Pharmaceuticals (HIK.LN) to equalweight from overweight but raises price target to 750p from 700p. The bank says a Middle East and North Africa site visit confirmed fundamentals, but MS says the scope for upgrades is limited and the potential risk
Read morePharmaceutical firm Hikma has maintained its guidance for 2010 revenue growth in the low teens, with gross margin broadly in line with 2009. The group said it continues to expect Branded sales growth in the low double digits for the full year due to the disruption in the Algerian market in the begi
Read moreNorth Sea oil and gas explorer and producer EnQuest is one of the best performers in the FTSE 250 index on the back of buying by non-executive director Alexandre Schneiter. EnQuest was demerged from oil services provider Petrofac on 6 April. Petrofac stayed in the FTSE 100 index but EnQuest fell o
Read moreHikma Pharmaceuticals is to take full ownership of the Algerian company Al Dar Al Arabia Pharmaceutical Manufacturing. Jordan-based pharmaceutical company Hikma is paying $18.5m for Dar Al Dawa's 50% stake in the joint venture. Al Dar Al Arabia owns a recently built 6,000 square metre manufacturin
Read moreSimon Bentley, a non-executive director in Mike Ashley's Sports Direct International, has sold four-fifths of his shareholding. Bentley raised £213,000 from selling 200,000 shares at 106.55p each. That leaves Bentley with 50,000 shares in the sports goods retailer. Bentley is a former chairman o
Read morePharmaceutical firm Hikma has agreed to increase its interest in Industries Pharmaceutiques Ibn Al Baytar, a Tunisian pharmaceutical manufacturing and marketing company, to 66%. Hikma will pay a consideration of $5million for the additional interest which will be satisfied from existing cash resour
Read moreHikma's forecast of "low teens" growth in branded drugs in 2010 was lower than some stockbrokers ? such as Panmure Gordon ? had been expecting. The corollary is that Hikma expects US generic drugs and injectable medicines, its two other businesses, to grow more strongly than before. But at 580p, d
Read moreLondon's gains were trimmed just before the close as traders took a few profits before heading off to celebrate St. Patrick's Day. Nevertheless, it was the highest close for the Footsie since the middle of 2008. Mining stocks led the advance, despite conflicting views in the broking community on th
Read moreA firm opening by Wall Street gave UK shares an additional fillip over the lunchtime trading session. Miners are leading the advance, despite conflicting views in the broking community on their merits. Societe Generale is in the bearish camp, cutting sector giants BHP Billiton and Rio Tinto from 'b
Read moreHedge fund manager Man Group is comfortably the highest yielding stock among FTSE 100 constituents, but a rebasing - a City euphemism for a cut - of the dividend could be on the way, according to Morgan Stanley. The shares are currently yielding 11.77% based on historical dividend payments and thou
Read moreLondon is now handily higher, with the strength of transport groups and miners cancelling out the subdued performance of ex-dividend stocks such as HSBC, Standard Life and Thomas Cook. The main point of interest is confirmation from bus and rail group Arriva that it has had an unsolicited bid appr
Read moreBroker Panmure Gordon was predicting yesterday that results from Hikma would be ahead of market expectations, so the in-line with consensus performance from the generic drugs producer came as a disappointment. The outlook statement also served to sap market enthusiasm for the stock in early trading
Read moreHikma Pharmaceuticals is weighing on the pharmaceutical sector even after it reported a 33% increase in 2009 operating profit and said it was confident of continuing growth. Broker Panmure Gordon was predicting yesterday that results from Hikma would be ahead of market expectations, so the in-line
Read more
Last checked at